The U.S. Centers for Disease Control and Prevention’s (CDC) panel of experts voted on Wednesday against recommending the respiratory syncytial virus (RSV) vaccine for all older adults.
Instead, the Advisory Committee on Immunization Practices (ACIP) concluded that anyone aged 60 and older “may” consider receiving a single dose of either Pfizer’s or GSK’s new RSV vaccine and that the decision should be made through shared clinical decision-making, based on a thorough risk assessment, in consultation with their doctors.
